Targeted therapies in bone sarcomas: Current approach and future directions

Expert Opinion on Investigational Drugs

Volumn 20, Issue 7, 2011, Pages 973-979

  Yarber, Jessica Lee ^a   Agulnik, Mark ^a  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

Author keywords

bone sarcoma; molecular targets; review; targeted therapy

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; DASATINIB; DROZITUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EVEROLIMUS; EXEMESTANE; EZRIN; FIGITUMUMAB; GENE THERAPY AGENT; IMATINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; ONCOPROTEIN; ORANTINIB; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE; PROTEIN WT 1; R 1507; RAPAMYCIN; RAPAMYCIN DERIVATIVE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; REXIN G; RIDAFOROLIMUS; SOMATOMEDIN C; TRASTUZUMAB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER RESISTANCE; CANCER SURVIVAL; CHONDROSARCOMA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG WITHDRAWAL; EWING SARCOMA; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LEUKOPENIA; MOLECULARLY TARGETED THERAPY; MUSCLE CRAMP; NONHUMAN; OSTEOCLASTOMA; OSTEOSARCOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; REVIEW; SARCOMA; SOFT TISSUE SARCOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; FORECASTING; HUMANS; OSTEOSARCOMA;

EID: 79958791448     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2011.577064     Document Type: Review

References (52)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58(2):71-96
2. Hauben EI, Arends J, Vandenbroucke JP, et al. Multiple primary malignancies in osteosarcoma patients. Incidence and predictive value of osteosarcoma subtype for cancer syndromes related with osteosarcoma. Eur J Hum Genet 2003;11(8):611-18 (Pubitemid 37038776)
3. Yu CL, Tucker MA, Abramson DH, et al. Cause-specific mortality in long-term survivors of retinoblastoma. J Natl Cancer Inst 2009;101(8):581-91
4. Fuchs B, Pritchard DJ. Etiology of osteosarcoma. Clin Orthop Relat Res 2002;(397):40-52 (Pubitemid 34442014)
5. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program. Cancer 2009;115(7):1531-43
6. Huvos AG. Osteogenic sarcoma of bones and soft tissues in older persons. A clinicopathologic analysis of 117 patients older than 60 years. Cancer 1986;57(7):1442-9 (Pubitemid 16136770)
7. Le Vu B, de Vathaire F, Shamsaldin A, et al. Radiation dose, chemotherapy and risk of osteosarcoma after solid tumours during childhood. Int J Cancer 1998;77(3):370-7 (Pubitemid 28299872)
8. Nellissery MJ, Padalecki SS, Brkanac Z, et al. Evidence for a novel osteosarcoma tumor-suppressor gene in the chromosome 18 region genetically linked with Paget disease of bone. Am J Hum Genet 1998;63(3):817-24 (Pubitemid 30422682)
9. Tang N, Song WX, Luo J, et al. Osteosarcoma development and stem cell differentiation. Clin Orthop Relat Res 2008;466(9):2114-30
10. Tsukita S, Yonemura S. ERM (ezrin/radixin/moesin) family: from cytoskeleton to signal transduction. Curr Opin Cell Biol 1997;9(1):70-5 (Pubitemid 27065111)
11. Ferguson W, Goorin AM. Current treatment of osteosarcoma. Cancer Invest 2001;19(3):23
12. Stiller C, Bielack SS, Jundt G, et al. Bone tumours in European children and adolescents, 1978-1997. Report from the Automated Childhood Cancer Information System Project. Eur J Cancer 2006;42(13):11
13. Miller R. Contrast epidemiology of childhood osteosarcoma, Ewing's tumor and rhabdomyosarcoma. Natl Cancer Inst Monogr 1981;(56):9-15 (Pubitemid 12193839)
14. de Alava E, Gerald WL. Molecular biology of the Ewing's sarcoma/primitive neuroectodermal tumor family. J Clin Oncol 2000;18(1):204-13 (Pubitemid 30036354)
15. Zucman J, Delattre O, Desmaze C, et al. Cloning and characterization of the Ewing's sarcoma and peripheral neuroepithelioma t(11;22) translocation breakpoints. Genes Chromosomes Cancer 1992;5(4):271-7 (Pubitemid 23011196)
16. Prieur A, Tirode F, Cohen P, Delattre O. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 2004;24(16):7275-83 (Pubitemid 39014452)
17. Cironi L, Riggi N, Provero P, et al. IGF1 is a common target gene of Ewing's sarcoma fusion proteins in mesenchymal progenitor cells. PLoS One 2008;3(7):e2634
18. Tirado OM, Mateo-Lozano S, Villar J, et al. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells. Cancer Res 2006;66(20):9937-47 (Pubitemid 44672046)
19. Kinsey M, Smith R, Lessnick SL. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma. Mol Cancer Res 2006;4(11):851-9 (Pubitemid 44877015)
20. Smith R, Owen LA, Trem DJ, et al. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Cancer Cell 2006;9(5):405-16 (Pubitemid 43668735)
21. Luo W, Gangwal K, Sankar S, et al. GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance. Oncogene 2009;28(46):4126-32
22. Takahashi A, Higashino F, Aoyogi M, et al. EWS/ETS fusions activate telomerase in Ewing's tumor. Cancer Res 2003;63(23):6
23. Schwab JH, Boland PJ, Agaram NP, et al. Chordoma and chondrosarcoma gene profile: implications for immunotherapy. Cancer Immunol Immunother 2009;58(3):339-49
24. Lagonigro MS, Tamborini E, Negri T, et al. PDGFRalpha, PDGFRbeta and KIT expression/activation in conventional chondrosarcoma. J Pathol 2006;208(5):615-23
25. Grifone TJ, Haupt HM, Podolski V, Brooks JJ. Immunohistochemical expression of estrogen receptors in chondrosarcomas and enchondromas. Int J Surg Pathol 2008;16(1):31-7
26. Cleton-Jansen AM, van Beerendonk HM, Baelde HJ, et al. Estrogen signaling is active in cartilaginous tumors: implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma. Clin Cancer Res 2005;11(22):8028-35 (Pubitemid 41698744)
27. Dohi O, Hatori M, Suzuki T, et al. Sex steroid receptors expression and hormone-induced cell proliferation in human osteosarcoma. Cancer Sci 2008;99(3):518-23 (Pubitemid 351228568)
28. Gelderblom H, Hohenberger J, Bovee JV, et al. Aromatase inhibition in patients with recurrent and/or metastatic chondrosarcoma. 2008 ASCO Annual Meeting Proceedings. J Clin Oncol 2008;26:10542
29. Druker B. Imatinib (Gleevec) as a paradigm of targeted cancer therapies. Keio J Med 2010;59(1):1-3
30. Grignani G, Palmerini E, Stacchiotti S, et al. A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-alpha or-beta: an Italian Sarcoma Group study. Cancer 2011;117(4):826-31
31. Chao J, Budd GT, Chu P, et al. Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors. Anticancer Res 2010;30(2):547-52
32. Klenke FM, Abdollahi A, Bertl E, et al. Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo. BMC Cancer 2007;7:49
33. Schrage YM, Briaire-de Bruijn IH, de Miranda NF, et al. Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment. Cancer Res 2009;69(15):6216-22
34. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8(2):128-35 (Pubitemid 34155123)
35. Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 2004;10(2):182-6 (Pubitemid 38524889)
36. Brown EJ, Schreiber SL. A signaling pathway to translational control. Cell 1996;86(4):517-20 (Pubitemid 26299483)
37. Wan X, Mendoza A, Khanna C, Helman LJ. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 2005;65(6):2406-11 (Pubitemid 40490152)
38. Chawla S, Tolcher AW, Staddon AP, et al. Survival results with AP23573, a novel mTOR inhibitor, in patients with advanced soft tissue or bone sarcoma: update of phase II trial. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol 2007;25(18s):10076
39. Kappel CC, Velez-Yanguas MC, Hirschfeld S, Helman LJ. Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth. Cancer Res 1994;54(10):2803-7 (Pubitemid 24173778)
40. Olmos D, Postel-Vinay S, Molife LR, et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol 2010;11(2):129-35
41. Pappo A, Patel S, Crowley J, et al. Activity of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor in patients with recurrent or refractory Ewing's sarcoma family of tumors: results of a phase II SARC study. 2010 ASCO Annual Meeting Proceedings. J Clin Oncol 2010;25(15s):10000
42. Huang F, Greer A, Hurlburt W, et al. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res 2009;69(1):161-70
43. Scotlandi K, Manara MC, Hattinger CM, et al. Prognostic and therapeutic relevance of Her2 expression in osteosarcoma and Ewing's sarcoma. Eur J Cancer 2005;41(9):12
44. Ueda TK, Kakunaga S, Oka Y, et al. Tumor immunotherapy targeting WT1 (Wilms' tumor gene) peptide for bone and soft-tissue sarcomas: a preliminary report. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol 2007;25(18S):10042
45. Anninga JK, van de Vijver MJ, Cleton-Jansen AM, et al. Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcoma. Eur J Cancer 2004;40(7):2
46. Guan H, Jia SF, Zhou Z, et al. Herceptin down-regulates HER-2/neu and vascular endothelial growth factor expression and enhances taxol-induced cytotoxicity of human Ewing's sarcoma cells in vitro and in vivo. Clin Cancer Res 2005;1(11):11
47. Ueda T, Kakunaga S, Oka Y, et al. Tumor immunotherapy targeting WT1 (Wilms' tumor gene) peptide for bone and soft-tissue sarcomas: a preliminary report. Paper presented at: ASCO Annual Meeting Proceedings 2007
48. Herbst RS, Eckhardt SG, Kurzrock R, et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 2010;28(17):2839-46
49. Chawla SP, Chua VS, Fernandez L, et al. Phase I/II and phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy- resistant sarcoma and osteosarcoma. Mol Ther 2009;17(9):1651-7
50. Lau Y, Sabokbar A, Gibbons CL. Phenotypic and molecular studies of giant cell tumor of bone and soft tissue. Hum Pathol 2005;36(9):9
51. Thomas DM, Chawla S, Skubitz A, et al. Denosumab for the treatment of giant cell tumor (GCT) of bone: final results form a proof-of-concept phase II study. Paper presented at: 2009 ASCO Annual Metting 2009
52. Pisters PW, Leung DH, Woodruff J, et al. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 1996;14:10